CEPI, the Coalition for Epidemic Preparedness Innovations, awarded Public Health Vaccines LLC 1.9 million dollars on 9 June to generate master viral seed stock for a fourth Bundibugyo vaccine candidate on the rVSV platform1. CEPI is the Oslo-based public-private coalition that funds early-stage pandemic vaccine development. The rVSV platform takes a harmless virus and engineers it to carry the pathogen's immune markers, the same approach behind the licensed Zaire Ebola vaccine.
The award brings CEPI's Bundibugyo portfolio to four candidates across three platforms, roughly 63.7 million dollars in total, advancing on the three-platform commitment of early June. Master seed stock sits at the front of the bottleneck most vaccine timelines hide. The rVSV process depends on specialised cell-culture inputs that take months to establish, which is why funding the seed stock now, rather than when a candidate is ready for human testing, shortens the path to a Phase 1 trial later.
Africa CDC flags the gap underneath all of it. No Bundibugyo-specific rapid diagnostic test exists, so every suspected case still waits on a PCR laboratory assay, the polymerase chain reaction method that amplifies viral genetic material, rather than a bedside test that returns an answer in minutes. In Ituri's insecure health zones, the lag between swab and result is the same lag that keeps patients out of isolation and prolongs every transmission chain.
